Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986619000087/alxn630201910q.htm
July 2021
July 2021
May 2021
May 2021
April 2021
March 2021
February 2021
February 2021
January 2021
December 2020
• | 2Q19 total revenues of $1,203.3 million, a 15 percent increase over 2Q18 and a 23 percent volume increase |
• | 2Q19 GAAP diluted EPS of $2.04; non-GAAP diluted EPS of $2.64 |
• | Received 3 regulatory approvals - SOLIRIS® (eculizumab) for adults with neuromyelitis optica spectrum disorder (NMOSD) in the U.S., and ULTOMIRIS® (ravulizumab-cwvz) for adults with paroxysmal nocturnal hemoglobinuria (PNH) in Japan and the EU |
• | ULTOMIRIS for atypical hemolytic uremic syndrome (aHUS) under priority review with U.S. FDA |
• | Total revenues and EPS guidance increased to reflect strength of the business and continued growth |
• | Total net product sales were $1,202.5 million in the second quarter of 2019, compared to $1,044.7 million in the second quarter of 2018. |
• | SOLIRIS® (eculizumab) net product sales were $980.8 million, compared to $898.2 million in the second quarter of 2018, representing a 9 percent increase. SOLIRIS volume increased 17 percent year-over-year. SOLIRIS net product sales for the second quarter 2019 included a $31.6 million reduction to revenue related to a recent judicial order on SOLIRIS pricing in Canada. The reduction in revenue includes the impact for the period from September 2017 to June 2019. |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986619000087/alxn630201910q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Alexion Pharmaceuticals, Inc..
Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Rating
Learn More![]()
Generalized Myasthenia Gravis (gMG) Myasthenia Gravis (MG) is a debilitating, complement-mediated neuromuscular disease in which patients suffer profound muscle weakness throughout the body, resulting in slurred speech, impaired swallowing and choking, double vision, upper and lower extremity weakness, disabling fatigue, shortness of breath due to respiratory muscle weakness and episodes of respiratory failure.
49 49 Alexion Pharmaceuticals, Inc. (amounts in millions, except per share amounts) Alexion Pharmaceuticals, Inc. (amounts in millions, except per share amounts) Financial Condition, Liquidity and Capital Resources The following table summarizes the components of our financial condition as of June 30, 2019 and December 31, 2018: The aggregate increase in cash and cash equivalents and marketable securities of $525.8 at June 30, 2019 as compared to December 31, 2018 was primarily attributable to cash generated from operations and net proceeds from the issuance of common stock under share-based compensation arrangements.
We expect increases in cash flows from operations, if any, which will be highly dependent on sales levels and the related cash collections from sales of our products.
We expect increases in cash flows from operations, if any, which will be highly dependent on sales levels and the related cash collections from sales of our products.
We expect increases in cash flows from operations, if any, which will be highly dependent on sales levels and the related cash collections from sales of our products.
48 48 Alexion Pharmaceuticals, Inc....Read more
Selling, General and Administrative Expense...Read more
Partially offset by the following:...Read more
We anticipate that cash generated...Read more
We anticipate that cash generated...Read more
The increase in cash used...Read more
The increase in cash used...Read more
The increase in cash used...Read more
This deferred tax cost increased...Read more
This deferred tax cost increased...Read more
In February 2017, our Board...Read more
As Financial Condition, Liquidity and...Read more
Partially offset by the following:...Read more
The agreement became effective in...Read more
However, readers should carefully review...Read more
(see Note 19) Other Income...Read more
Amortization of Purchase Intangible Assets...Read more
Amortization of Purchase Intangible Assets...Read more
New sources of financing through...Read more
Partially offsetting these increases was...Read more
Partially offsetting these increases was...Read more
Partially offsetting these increases was...Read more
To date, we have not...Read more
To date, we have not...Read more
The increase in cash used...Read more
The increase in cash used...Read more
The increase in cash used...Read more
In January 2019 we paid...Read more
In January 2019 we paid...Read more
In January 2019 we paid...Read more
The increase in cash was...Read more
The increase in cash was...Read more
The increase in cash was...Read more
Accordingly, the value of the...Read more
Accordingly, the value of the...Read more
40 40 Alexion Pharmaceuticals, Inc....Read more
The increase in net product...Read more
The income tax expense for...Read more
The income tax expense for...Read more
The stated objectives of our...Read more
Under the terms of the...Read more
The increase was primarily related...Read more
Clinical development costs are comprised...Read more
The agreement with Affibody was...Read more
The agreement with Affibody was...Read more
The agreement with Affibody was...Read more
The Company did not repurchase...Read more
These selling, general and administrative...Read more
The six months ended June...Read more
The deferred tax benefits include...Read more
While ULTOMIRIS contributed to the...Read more
Decrease of $5.2 in external...Read more
Other R&D expenses consist of...Read more
Excluding the impact of any...Read more
Excluding the impact of any...Read more
Excluding the impact of any...Read more
As a result of strategic...Read more
This increase in unit volumes...Read more
This increase in unit volumes...Read more
We operate in certain jurisdictions...Read more
We operate in certain jurisdictions...Read more
We operate in certain jurisdictions...Read more
Increase of $6.4 in payroll...Read more
Increase of $13.0 in payroll...Read more
We manage our foreign currency...Read more
Acquired In-Process Research and Development...Read more
We have financed our operations...Read more
Under the terms of the...Read more
Under the terms of the...Read more
Under the terms of the...Read more
To the extent CFC earnings...Read more
To the extent CFC earnings...Read more
We cannot guarantee that results...Read more
We believe the judgments, estimates...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Alexion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ALXN
CIK: 899866
Form Type: 10-Q Quarterly Report
Accession Number: 0000899866-19-000087
Submitted to the SEC: Wed Jul 24 2019 4:00:01 AM EST
Accepted by the SEC: Wed Jul 24 2019
Period: Sunday, June 30, 2019
Industry: Pharmaceutical Preparations